Last reviewed · How we verify
Hydroxyzine Pill
Hydroxyzine Pill, marketed by Rose Research Center, LLC, holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection offered by its patent until 2028. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Hydroxyzine Pill |
|---|---|
| Also known as | Atarax 10mg |
| Sponsor | Rose Research Center, LLC |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of Cetirizine HCl on Exercise-induced Arterial Hypoxemia in Highly-trained Swimmers (PHASE4)
- Comparison Between Oral Melatonin and Hydroxyzine in Pediatric Patients Undergoing Adenotonsillectomy (PHASE1)
- Efficacy and Tolerability of Combination Varenicline With Hydroxyzine as a Potential Smoking Cessation Treatment (PHASE4)
- Cetirizine and Famotidine for COVID-19 (PHASE4)
- Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel (PHASE3)
- Transporters for Organic Cations and Glycemic Control in Patients With Neuropathic Pain. (PHASE4)
- Comparability and Standardization of Controlled Allergen Challenge Facilities (PHASE4)
- Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydroxyzine Pill CI brief — competitive landscape report
- Hydroxyzine Pill updates RSS · CI watch RSS
- Rose Research Center, LLC portfolio CI